Ayurveda botanicals in COVID-19 management: An in silico multi-target approach
Open Access
- 11 June 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6) , e0248479
Abstract
The Coronavirus disease (COVID-19) caused by the virus SARS-CoV-2 has become a global pandemic in a very short time span. Currently, there is no specific treatment or vaccine to counter this highly contagious disease. There is an urgent need to find a specific cure for the disease and global efforts are directed at developing SARS-CoV-2 specific antivirals and immunomodulators. AyurvedicRasayanatherapy has been traditionally used in India for its immunomodulatory and adaptogenic effects, and more recently has been included as therapeutic adjuvant for several maladies. Amongst several others,Withania somnifera(Ashwagandha),Tinospora cordifolia(Guduchi) andAsparagus racemosus(Shatavari) play an important role inRasayanatherapy. The objective of this study was to explore the immunomodulatory and anti SARS-CoV2 potential of phytoconstituents from Ashwagandha, Guduchi and Shatavari using network pharmacology and docking. The plant extracts were prepared as per ayurvedic procedures and a total of 31 phytoconstituents were identified using UHPLC-PDA and mass spectrometry studies. To assess the immunomodulatory potential of these phytoconstituents anin-siliconetwork pharmacology model was constructed. The model predicts that the phytoconstituents possess the potential to modulate several targets in immune pathways potentially providing a protective role. To explore if these phytoconstituents also possess antiviral activity, docking was performed with the Spike protein, Main Protease and RNA dependent RNA polymerase of the virus. Interestingly, several phytoconstituents are predicted to possess good affinity for the three targets, suggesting their application for the termination of viral life cycle. Further, predictive tools indicate that there would not be adverse herb-drug pharmacokinetic-pharmacodynamic interactions with concomitantly administered drug therapy. We thus make a compelling case to evaluate the potential of theseRasayanabotanicals as therapeutic adjuvants in the management of COVID-19 following rigorous experimental validation.Keywords
All Related Versions
Funding Information
- Ministry of AYUSH, Govt. of India (Z 15015/07/2017-COE; Dt. 27/11/2017)
This publication has 86 references indexed in Scilit:
- Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania somnifera’s key metabolite Withaferin AIn Silico Pharmacology, 2013
- GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkitBioinformatics, 2013
- Tinospora cordifolia: One plant, many rolesAncient Science of Life, 2012
- CurlySMILES: a chemical language to customize and annotate encodings of molecular and nanodevice structuresJournal of Cheminformatics, 2011
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinitiesNucleic Acids Research, 2006
- Botanical immunodrugs: scope and opportunitiesDrug Discovery Today, 2005
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytesNature Immunology, 2002